EA201691539A1 - 2,7-диазаспиро[3.5]нонановые соединения - Google Patents
2,7-диазаспиро[3.5]нонановые соединенияInfo
- Publication number
- EA201691539A1 EA201691539A1 EA201691539A EA201691539A EA201691539A1 EA 201691539 A1 EA201691539 A1 EA 201691539A1 EA 201691539 A EA201691539 A EA 201691539A EA 201691539 A EA201691539 A EA 201691539A EA 201691539 A1 EA201691539 A1 EA 201691539A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- diazaspiro
- nonane
- connections
- compounds
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Данное изобретение относится к соединению формулы (I) или его стереоизомеру, энантиомеру, рацемической смеси или таутомеругде R, R, R, L, L, L, Lи n имеют значения, определенные в формуле и описании изобретения. Данное изобретение также относится к композициям, в частности фармацевтическим композициям, содержащим такие соединения, и к использованию таких соединений и композиций для профилактики и/или лечения метаболических расстройств и/или нейродегенеративных заболеваний, и/или расстройств мисфолдинга белка.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14160344 | 2014-03-17 | ||
PCT/EP2015/055494 WO2015140132A1 (en) | 2014-03-17 | 2015-03-17 | 2,7-diazaspiro[3.5]nonane compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201691539A1 true EA201691539A1 (ru) | 2017-01-30 |
EA032470B1 EA032470B1 (ru) | 2019-05-31 |
Family
ID=50287962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201691539A EA032470B1 (ru) | 2014-03-17 | 2015-03-17 | 2,7-диазаспиро[3.5]нонановые соединения |
Country Status (17)
Country | Link |
---|---|
US (2) | US9617264B2 (ru) |
EP (1) | EP3119782B1 (ru) |
JP (2) | JP6574438B2 (ru) |
CN (1) | CN106103439B (ru) |
AU (1) | AU2015233642B2 (ru) |
CA (1) | CA2941196C (ru) |
DK (1) | DK3119782T3 (ru) |
EA (1) | EA032470B1 (ru) |
ES (1) | ES2666173T3 (ru) |
HR (1) | HRP20180585T1 (ru) |
HU (1) | HUE038764T2 (ru) |
NO (1) | NO3119782T3 (ru) |
PL (1) | PL3119782T3 (ru) |
PT (1) | PT3119782T (ru) |
RS (1) | RS57129B1 (ru) |
SI (1) | SI3119782T1 (ru) |
WO (1) | WO2015140132A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201416351D0 (en) | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Heterocyclic derivatives |
GB201416352D0 (en) | 2014-09-16 | 2014-10-29 | Shire Internat Gmbh | Spirocyclic derivatives |
US11149022B2 (en) | 2017-10-17 | 2021-10-19 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
JP2024505537A (ja) * | 2021-01-29 | 2024-02-06 | コリア リサーチ インスティチュート オブ ケミカル テクノロジー | ベンゾチアゾール及びベンズイミダゾール誘導体、薬学的に許容可能な塩、その製造方法及びそれを有効成分として含む医薬組成物 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080247964A1 (en) * | 2006-05-08 | 2008-10-09 | Yuelian Xu | Substituted azaspiro derivatives |
CA2663947A1 (en) | 2006-09-15 | 2008-03-20 | Schering Corporation | Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism |
JP5496409B2 (ja) | 2010-03-19 | 2014-05-21 | ファイザー・インク | 2,3ジヒドロ−1h−インデン−1−イル−2,7−ジアザスピロ[3.5]ノナン誘導体およびグレリン受容体のアンタゴニストまたは逆アゴニストとしてのそれらの使用 |
EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
CN104364239B (zh) * | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
-
2015
- 2015-03-17 NO NO15710486A patent/NO3119782T3/no unknown
- 2015-03-17 SI SI201530219T patent/SI3119782T1/en unknown
- 2015-03-17 HU HUE15710486A patent/HUE038764T2/hu unknown
- 2015-03-17 PL PL15710486T patent/PL3119782T3/pl unknown
- 2015-03-17 PT PT157104860T patent/PT3119782T/pt unknown
- 2015-03-17 EP EP15710486.0A patent/EP3119782B1/en active Active
- 2015-03-17 DK DK15710486.0T patent/DK3119782T3/en active
- 2015-03-17 CN CN201580013644.7A patent/CN106103439B/zh not_active Expired - Fee Related
- 2015-03-17 JP JP2016557898A patent/JP6574438B2/ja active Active
- 2015-03-17 RS RS20180427A patent/RS57129B1/sr unknown
- 2015-03-17 US US15/121,790 patent/US9617264B2/en active Active
- 2015-03-17 CA CA2941196A patent/CA2941196C/en active Active
- 2015-03-17 AU AU2015233642A patent/AU2015233642B2/en not_active Ceased
- 2015-03-17 EA EA201691539A patent/EA032470B1/ru not_active IP Right Cessation
- 2015-03-17 WO PCT/EP2015/055494 patent/WO2015140132A1/en active Application Filing
- 2015-03-17 ES ES15710486.0T patent/ES2666173T3/es active Active
-
2017
- 2017-02-15 US US15/433,164 patent/US9750745B2/en active Active
-
2018
- 2018-04-12 HR HRP20180585TT patent/HRP20180585T1/hr unknown
-
2019
- 2019-05-20 JP JP2019094697A patent/JP2019147834A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP3119782A1 (en) | 2017-01-25 |
US9617264B2 (en) | 2017-04-11 |
US20170015665A1 (en) | 2017-01-19 |
CN106103439A (zh) | 2016-11-09 |
PL3119782T3 (pl) | 2018-07-31 |
AU2015233642B2 (en) | 2017-08-03 |
CN106103439B (zh) | 2019-03-08 |
DK3119782T3 (en) | 2018-03-12 |
AU2015233642A1 (en) | 2016-09-08 |
JP2019147834A (ja) | 2019-09-05 |
US9750745B2 (en) | 2017-09-05 |
HRP20180585T1 (hr) | 2018-07-13 |
EP3119782B1 (en) | 2018-01-31 |
JP2017507986A (ja) | 2017-03-23 |
CA2941196A1 (en) | 2015-09-24 |
NO3119782T3 (ru) | 2018-06-30 |
SI3119782T1 (en) | 2018-06-29 |
HUE038764T2 (hu) | 2018-11-28 |
JP6574438B2 (ja) | 2019-09-11 |
WO2015140132A1 (en) | 2015-09-24 |
CA2941196C (en) | 2019-09-03 |
ES2666173T3 (es) | 2018-05-03 |
US20170157137A1 (en) | 2017-06-08 |
PT3119782T (pt) | 2018-04-17 |
RS57129B1 (sr) | 2018-07-31 |
EA032470B1 (ru) | 2019-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792047A1 (ru) | Новые соединения | |
EA201990495A1 (ru) | Биарильные соединения, применимые в качестве иммуномодуляторов | |
EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201790492A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
EA201592143A1 (ru) | Новые бициклические ингибиторы бромодомена | |
PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
EA201890086A1 (ru) | 1,4-замещенные производные пиперидина | |
EA201891974A1 (ru) | Ингибиторы связывания белка wdr5 с белками | |
EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
EA201691940A1 (ru) | Новые соединения | |
EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
EA201691857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
EP3778605A3 (en) | Lrrk2 inhibitors and methods of making and using the same | |
EA201592024A1 (ru) | Замещенные 5-(3,5-диметилизоксазол-4-ил)-индолин-2-оны | |
EA201691853A1 (ru) | Агонисты мускариновых рецепторов | |
EA201791733A1 (ru) | Производные 9h-пирролодипиридина | |
EA201990400A1 (ru) | Соединения и композиции и их применение | |
EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
EA201692049A1 (ru) | Гетероарилзамещенные гетероциклилсульфоны | |
EA202090414A1 (ru) | Соединения и их применение | |
EA201691539A1 (ru) | 2,7-диазаспиро[3.5]нонановые соединения | |
EA201691141A1 (ru) | Соединения против ccr6 | |
EA201700042A1 (ru) | Соединения имидазопиридазина | |
EA201790570A1 (ru) | Модуляторы р2х7 | |
EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM |